keyword
MENU ▼
Read by QxMD icon Read
search

CheckMate

keyword
https://www.readbyqxmd.com/read/28131785/nivolumab-in-metastatic-urothelial-carcinoma-after-platinum-therapy-checkmate-275-a-multicentre-single-arm-phase-2-trial
#1
Padmanee Sharma, Margitta Retz, Arlene Siefker-Radtke, Ari Baron, Andrea Necchi, Jens Bedke, Elizabeth R Plimack, Daniel Vaena, Marc-Oliver Grimm, Sergio Bracarda, José Ángel Arranz, Sumanta Pal, Chikara Ohyama, Abdel Saci, Xiaotao Qu, Alexandre Lambert, Suba Krishnan, Alex Azrilevich, Matthew D Galsky
BACKGROUND: Patients with metastatic urothelial carcinoma have a dismal prognosis and few treatment options after first-line chemotherapy. Responses to second-line treatment are uncommon. We assessed nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, for safety and activity in patients with metastatic or surgically unresectable urothelial carcinoma whose disease progressed or recurred despite previous treatment with at least one platinum-based chemotherapy regimen...
January 25, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/27997007/-new-perspectives-in-second-line-treatment-in-non-squamous-non-small-cell-lung-cancer
#2
Francesco Grossi
The treatment options for patients with non-squamous non-small cell lung cancer (NSCLC) in second-line have been limited for a long time. Docetaxel, pemetrexed and erlotinib are the standard second-line treatment. Docetaxel is frequently used although it is associated with an unfavorable safety profile. Recently, the results from the trial CheckMate 057 with nivolumab, an anti-PD-1 inhibitor, has increased the therapeutic options for patients with non-squamous NSCLC in the second-line setting. The results of this randomized phase III trial comparing nivolumab vs docetaxel have deeply changed our current clinical practice...
December 2016: Recenti Progressi in Medicina
https://www.readbyqxmd.com/read/27969526/ps01-59-checkmate-370-a-master-protocol-of-phase-1-2-studies-of-nivolumab-as-maintenance-or-first-line-%C3%A2-standard-of-care-therapies-in-advanced-nsclc-topic-medical-oncology
#3
George Blumenschein, Jason Chandler, Edward B Garon, David Waterhouse, Jonathan W Goldman, Vijay K Gunuganti, Ralph Boccia, David Spigel, John Glaspy, Donald A Berry, Beata Korytowsky, Jin Zhu, Wen Hong Lin, Kelly Bennett, Craig Reynolds
No abstract text is available yet for this article.
November 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27969442/oral01-03-checkmate-012-safety-and-efficacy-of-first-line-nivolumab-and-ipilimumab-in-advanced-nsclc-topic-medical-oncology
#4
Scott J Antonia, Scott N Gettinger, Jonathan Goldman, Julie Brahmer, Hossein Borghaei, Laura Q Chow, Neal E Ready, David E Gerber, Rosalyn Juergens, Frances Shepherd, Scott A Laurie, Tina Young, William J Geese, Shruti Agrawal, Xuemei Li, Matthew D Hellmann
No abstract text is available yet for this article.
November 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27932067/nivolumab-plus-ipilimumab-as-first-line-treatment-for-advanced-non-small-cell-lung-cancer-checkmate-012-results-of-an-open-label-phase-1-multicohort-study
#5
Matthew D Hellmann, Naiyer A Rizvi, Jonathan W Goldman, Scott N Gettinger, Hossein Borghaei, Julie R Brahmer, Neal E Ready, David E Gerber, Laura Q Chow, Rosalyn A Juergens, Frances A Shepherd, Scott A Laurie, William J Geese, Shruti Agrawal, Tina C Young, Xuemei Li, Scott J Antonia
BACKGROUND: Nivolumab has shown improved survival in the treatment of advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy. We assessed the safety and activity of combination nivolumab plus ipilimumab as first-line therapy for NSCLC. METHODS: The open-label, phase 1, multicohort study (CheckMate 012) cohorts reported here were enrolled at eight US academic centres. Eligible patients were aged 18 years or older with histologically or cytologically confirmed recurrent stage IIIb or stage IV, chemotherapy-naive NSCLC...
January 2017: Lancet Oncology
https://www.readbyqxmd.com/read/27826379/checkmate-and-devil-s-tower
#6
(no author information available yet)
No abstract text is available yet for this article.
September 2016: Methodist DeBakey Cardiovascular Journal
https://www.readbyqxmd.com/read/27782862/acquired-resistance-to-anti-pd1-therapy-checkmate-to-checkpoint-blockade
#7
Jake S O'Donnell, Mark J Smyth, Michele W L Teng
Anti-programmed cell death 1 (PD1) immunotherapies are among the most effective anti-cancer immunotherapies available; however, a large number of patients present with or develop resistance to them. Unfortunately, very little is known regarding the mechanisms of resistance to such therapies. A recent study sought to identify mutations associated with resistance to anti-PD1 therapy. Results from this study demonstrated that mutations which affected the sensitivity of tumor cells to T-cell-derived interferons, and mutations limiting tumor-cell antigen presentation, could cause acquired resistance...
October 25, 2016: Genome Medicine
https://www.readbyqxmd.com/read/27733243/nivolumab-monotherapy-in-recurrent-metastatic-urothelial-carcinoma-checkmate-032-a-multicentre-open-label-two-stage-multi-arm-phase-1-2-trial
#8
Padmanee Sharma, Margaret K Callahan, Petri Bono, Joseph Kim, Pavlina Spiliopoulou, Emiliano Calvo, Rathi N Pillai, Patrick A Ott, Filippo de Braud, Michael Morse, Dung T Le, Dirk Jaeger, Emily Chan, Chris Harbison, Chen-Sheng Lin, Marina Tschaika, Alex Azrilevich, Jonathan E Rosenberg
BACKGROUND: Few effective treatments exist for patients with advanced urothelial carcinoma that has progressed after platinum-based chemotherapy. We assessed the activity and safety of nivolumab in patients with locally advanced or metastatic urothelial carcinoma whose disease progressed after previous platinum-based chemotherapy. METHODS: In this phase 1/2, multicentre, open-label study, we enrolled patients (age ≥18 years) with urothelial carcinoma of the renal pelvis, ureter, bladder, or urethra at 16 sites in Finland, Germany, Spain, the UK, and the USA...
November 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27718784/nivolumab-for-recurrent-squamous-cell-carcinoma-of-the-head-and-neck
#9
RANDOMIZED CONTROLLED TRIAL
Robert L Ferris, George Blumenschein, Jerome Fayette, Joel Guigay, A Dimitrios Colevas, Lisa Licitra, Kevin Harrington, Stefan Kasper, Everett E Vokes, Caroline Even, Francis Worden, Nabil F Saba, Lara C Iglesias Docampo, Robert Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Manish Monga, Mark Lynch, William J Geese, Justin Kopit, James W Shaw, Maura L Gillison
Background Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum chemotherapy have a very poor prognosis and limited therapeutic options. Nivolumab, an anti-programmed death 1 (PD-1) monoclonal antibody, was assessed as treatment for this condition. Methods In this randomized, open-label, phase 3 trial, we assigned, in a 2:1 ratio, 361 patients with recurrent squamous-cell carcinoma of the head and neck whose disease had progressed within 6 months after platinum-based chemotherapy to receive nivolumab (at a dose of 3 mg per kilogram of body weight) every 2 weeks or standard, single-agent systemic therapy (methotrexate, docetaxel, or cetuximab)...
November 10, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27676580/p2-46-also-presented-as-pd1-01-lcss-as%C3%A2-a%C3%A2-marker-of-treatment-benefit%C3%A2-with-nivolumab-vs-docetaxel-in%C3%A2-pts-with-advanced-non-squamous-nsclc-from-checkmate-057-track-immunotherapy
#10
Richard J Gralla, David Spigel, Bryan Bennett, Fiona Taylor, John R Penrod, Michael Derosa, Homa Dastani, Lucinda Orsini, Clarissa Mathias, Martin Reck
No abstract text is available yet for this article.
October 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27676569/p2-35-nivolumab-vs-docetaxel-in-advanced%C3%A2-nsclc-checkmate-017-057%C3%A2-2-y-update-and-exploratory-cytokine-profile-analysis-track-immunotherapy
#11
Hossein Borghaei, Julie Brahmer, Leora Horn, Neal Ready, Martin Steins, Enriqueta Felip, Luis Paz-Ares, Xx Xx, Fabrice Barlesi, Scott Antonia, Jérome Fayette, Naiyer Rizvi, Lucio Crino, Martin Reck, Wilfried Ernst Erich Eberhardt, Matthew Hellmann, Kaushal Desai, Ang Li, Diane Healey, David Spigel, Clarissa Mathias
No abstract text is available yet for this article.
October 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27676567/p2-33-safety-profile-of-nivolumab-administered-as-30-minute-min-infusion-analysis-of-data-from-checkmate-153-track-immunotherapy
#12
David Waterhouse, Leora Horn, Craig Reynolds, David Spigel, Jason Chandler, Tarek Mekhail, Mohamed Mohamed, Ben Creelan, Kenneth B Blankstein, Petros Nikolinakos, Michael J Mccleod, Ang Li, Ian M Waxman, Nivedita Aanur, Shruti Agrawal, Eduardo Richardet
No abstract text is available yet for this article.
October 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27676476/pd1-01-also-presented-as-p2-46-lcss-as-a-marker-of-treatment-benefit-with-nivolumab-vs-docetaxel-in-pts-with-advanced-non-squamous-nsclc-from-checkmate-057
#13
Richard J Gralla, David Spigel, Bryan Bennett, Fiona Taylor, John R Penrod, Michael Derosa, Homa Dastani, Lucinda Orsini, Clarissa Mathias, Martin Reck
No abstract text is available yet for this article.
October 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27660471/novel-chlorambucil-conjugated-anionic-linear-globular-peg-based-second-generation-dendrimer-in-vitro-in-vivo-improved-anticancer-activity
#14
Artin Assadi, Vahideh Sharifi Najafabadi, Seyed Ataollah Sadat Shandiz, Azadah Shayeq Boroujeni, Sepehr Ashrafi, Ali Zaman Vaziri, Seyedeh Masoumeh Ghoreishi, Mohammad Reza Aghasadeghi, Seyed Esmaeil Sadat Ebrahimi, Morteza Pirali-Hamedani, Mehdi Shafiee Ardestani
Evaluating the efficacy of anticancer drugs is an evolving and research-oriented issue. The objective of this study was to reduce the insolubility of chlorambucil (CBL) in water and improve the anticancer activity of CBL in vitro and in vivo through the conjugation of CBL with anionic linear-globular dendrimer (second generation, G2). In the current study, the anticancer activity among three groups that include CBL, CBL-G2 dendrimer, and control was measured in vitro and in vivo. In vitro studies showed that G2 anionic linear-globular polyethylene-glycol-based dendrimer, which conjugated to the CBL exterior through an ester linkage, was able to significantly improve the treatment efficacy over clinical CBL alone with respect to proliferation assay, 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide; half maximal inhibitory concentration (IC50) was calculated to be 141 µg/mL for CBL alone and 27...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27642308/vitamin-d-intake-and-its-protective-role-in-multiple-sclerosis-the-checkmate-to-survivin
#15
EDITORIAL
Raffaella Mormile
No abstract text is available yet for this article.
2016: Iranian Journal of Pharmaceutical Research: IJPR
https://www.readbyqxmd.com/read/27622997/combined-nivolumab-and-ipilimumab-versus-ipilimumab-alone-in-patients-with-advanced-melanoma-2-year-overall-survival-outcomes-in-a-multicentre-randomised-controlled-phase-2-trial
#16
F Stephen Hodi, Jason Chesney, Anna C Pavlick, Caroline Robert, Kenneth F Grossmann, David F McDermott, Gerald P Linette, Nicolas Meyer, Jeffrey K Giguere, Sanjiv S Agarwala, Montaser Shaheen, Marc S Ernstoff, David R Minor, April K Salama, Matthew H Taylor, Patrick A Ott, Christine Horak, Paul Gagnier, Joel Jiang, Jedd D Wolchok, Michael A Postow
BACKGROUND: Results from phase 2 and 3 trials in patients with advanced melanoma have shown significant improvements in the proportion of patients achieving an objective response and prolonged progression-free survival with the combination of nivolumab (an anti-PD-1 antibody) plus ipilimumab (an anti-CTLA-4 antibody) compared with ipilimumab alone. We report 2-year overall survival data from a randomised controlled trial assessing this treatment in previously untreated advanced melanoma...
November 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27621699/everolimus-in-the-management-of-metastatic-renal-cell-carcinoma-an-evidence-based-review-of-its-place-in-therapy
#17
REVIEW
Sebastiano Buti, Alessandro Leonetti, Alice Dallatomasina, Melissa Bersanelli
INTRODUCTION: Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, and its pathogenesis is strictly related to altered cellular response to hypoxia, in which mTOR signaling pathway is implicated. Everolimus, an mTOR serine/threonine kinase inhibitor, represents a therapeutic option for the treatment of advanced RCC. AIM: The objective of this article is to review the evidence for the treatment of metastatic RCC with everolimus. EVIDENCE REVIEW: Everolimus was approved for second- and third-line therapy in patients with advanced RCC according to the results of a Phase III pivotal trial that demonstrated a benefit in median progression-free survival of ~2 months compared to placebo after failure of previous lines of therapy, of which at least one was an anti-VEGFR tyrosine kinase inhibitor (TKI)...
2016: Core Evidence
https://www.readbyqxmd.com/read/27610613/preclinical-development-of-ipilimumab-and-nivolumab-combination-immunotherapy-mouse-tumor-models-in-vitro-functional-studies-and-cynomolgus-macaque-toxicology
#18
Mark J Selby, John J Engelhardt, Robert J Johnston, Li-Sheng Lu, Minhua Han, Kent Thudium, Dapeng Yao, Michael Quigley, Jose Valle, Changyu Wang, Bing Chen, Pina M Cardarelli, Diann Blanset, Alan J Korman
The monoclonal antibodies ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) have shown remarkable antitumor activity in an increasing number of cancers. When combined, ipilimumab and nivolumab have demonstrated superior activity in patients with metastatic melanoma (CHECKMATE-067). Here we describe the preclinical development strategy that predicted these clinical results. Synergistic antitumor activity in mouse MC38 and CT26 colorectal tumor models was observed with concurrent, but not sequential CTLA-4 and PD-1 blockade...
2016: PloS One
https://www.readbyqxmd.com/read/27604993/complete-response-to-nivolumab-monotherapy-in-a-treatment-naive-braf-wild-type-patient-with-advanced-mucosal-melanoma-and-elevated-lactate-dehydrogenase-a-case-report-from-a-phase-iii-trial
#19
Paolo A Ascierto, Vito Vanella, Antonio Maria Grimaldi, Festino Lucia, Marco Palla, Ester Simeone, Nicola Mozzillo
The anti-PD-1 agent, nivolumab, has been approved both as monotherapy and in combination with ipilimumab for the treatment of unresectable or metastatic melanoma in the USA and European Union. Here we present the case of a patient with treatment-naive, metastatic mucosal melanoma and baseline LDH approximately seven times the upper limit of normal. The patient was enrolled in a clinical trial (CheckMate 066) and achieved a partial response, followed by a durable complete response with nivolumab treatment. The patient's LDH levels were documented in each cycle and dropped markedly within 2 months, when partial response to treatment was already evident...
September 7, 2016: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/27538576/tumor-mutational-load-and-immune-parameters-across-metastatic-renal-cell-carcinoma-risk-groups
#20
Guillermo de Velasco, Diana Miao, Martin H Voss, A Ari Hakimi, James J Hsieh, Nizar M Tannir, Pheroze Tamboli, Leonard J Appleman, W Kimryn Rathmell, Eliezer M Van Allen, Toni K Choueiri
Patients with metastatic renal cell carcinoma (mRCC) have better overall survival when treated with nivolumab, a cancer immunotherapy that targets the immune checkpoint inhibitor programmed cell death 1 (PD-1), rather than everolimus (a chemical inhibitor of mTOR and immunosuppressant). Poor-risk mRCC patients treated with nivolumab seemed to experience the greatest overall survival benefit, compared with patients with favorable or intermediate risk, in an analysis of the CheckMate-025 trial subgroup of the Memorial Sloan Kettering Cancer Center (MSKCC) prognostic risk groups...
October 2016: Cancer Immunology Research
keyword
keyword
68498
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"